Enorama Pharma AB (OSTO:ERMA) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)

What is Enorama Pharma AB ROE % Adjusted to Book Value?

Enorama Pharma AB OSTO:ERMA 29 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 29/100 and a GF Value™ of kr0.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Enorama Pharma AB's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Enorama Pharma AB's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Enorama Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Enorama Pharma AB ROE % Adjusted to Book Value Related Terms

Enorama Pharma AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB ROE % Adjusted to Book Value Chart

Enorama Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-29.95

-147.19

-26.92

-12.30

0.00

Enorama Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-72.77	-42.09	0.00	0.00	0.00

OSTO:ERMA vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enorama Pharma AB ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's ROE % Adjusted to Book Value falls into.

Save Embed

29GF Score

Enorama Pharma AB OSTO:ERMA

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Enorama Pharma AB ROE % Adjusted to Book Value Calculation

Enorama Pharma AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Enorama Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

Enorama Pharma AB (OSTO:ERMA) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enorama Pharma AB and its competitors.

Is Enorama Pharma AB's ROE % Adjusted to Book Value too high?

Enorama Pharma AB's current ROE % Adjusted to Book Value is 0.00%. Overall, Enorama Pharma AB has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Enorama Pharma AB's ROE % Adjusted to Book Value compare to ZTS and UTHR?

Enorama Pharma AB's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?

A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Enorama Pharma AB stock overvalued right now?

Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.41, compared to a current price of kr0.30 — trading 27.8% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Enorama Pharma AB's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.30 is trading 27.8% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:ERMA:

ROE % Adjusted to Book Value: 0.00%
GF Value™: kr0.41 vs. price of kr0.30 (27.8% below fair value)
GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enorama Pharma AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:GABA XSAT:PMED XSAT:ODI OSTO:NEWBRY OSTO:VIVE XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77

Website https://www.enorama.se

Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.

29GF Score

Get the complete analysis for OSTO:ERMA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.30

Price

kr0.41

GF Value

View OSTO:ERMA Analysis

See ROE % Adjusted to Book Value data for all stocks →